The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Open accessAbstract
The steady-state basal plasma glucose and insulin concentrations are determined by their interaction in a feedback loop. A computer-solved model has been used to predict the homeostatic concentrations which arise from varying degrees beta-cell deficiency and insulin resistance. Comparison of a patient's fasting values with the model's predictions allows a quantitative assessment of the contributions of insulin resistance and deficient beta-cell function to the fasting hyperglycaemia (homeostasis model assessment, HOMA). The accuracy and precision of the estimate have been determined by comparison with independent measures of insulin resistance and beta-cell function using hyperglycaemic and euglycaemic clamps and an intravenous glucose tolerance test. The estimate of insulin resistance obtained by homeostasis model assessment correlated with estimates obtained by use of the euglycaemic clamp (Rs = 0.88, p less than 0.0001), the fasting insulin concentration (Rs = 0.81, p less than 0.0001), and the hyperglycaemic clamp, (Rs = 0.69, p less than 0.01). There was no correlation with any aspect of insulin-receptor binding. The estimate of deficient beta-cell function obtained by homeostasis model assessment correlated with that derived using the hyperglycaemic clamp (Rs = 0.61, p less than 0.01) and with the estimate from the intravenous glucose tolerance test (Rs = 0.64, p less than 0.05). The low precision of the estimates from the model (coefficients of variation: 31% for insulin resistance and 32% for beta-cell deficit) limits its use, but the correlation of the model's estimates with patient data accords with the hypothesis that basal glucose and insulin interactions are largely determined by a simple feed back loop.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Own result · 7 Own interpretation · 3 No full text of the sources · 1 Partly supported · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The fasting plasma insulin concentration is largely determined by the glucose concentration [3]”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Summary.
What the sources say
- Partly supportedcites [3] McCarthy ST, Harris F, Turner RC (1977) Glucose control of basal insulin secretion in diabetes. Diabetologia 13: 93?97 sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable in our copy) show that changing plasma glucose affects basal insulin secretion. But they also report markedly impaired responses in diabetic subjects, including cases where insulin remained nearly constant despite a substantial glucose decrease. The paper therefore supports glucose as an influence, but not the unqualified claim that it largely determines fasting insulin concentration. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimate of deficient/3cell function obtained by homeostasis model assessment correlated with that derived using the hyperglycaemic clamp (R~ = 0.61, p< 0.01)”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Summary.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimate of insulin resistance obtained by homeostasis model assessment correlated with estimates obtained by use of the euglycaemic clamp (R~=0.88,p<0.0001)”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Summary.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no correlation with any aspect of insulin-receptor binding.”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Summary.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the fasting insulin concentration (P~ = 0.81, p < 0.0001)”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Summary.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean coefficient of variation over the two studies was 32%.”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Reproducibility of estimate of /3-cell function by HOMA
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in both groups together (1% 0.61, p < 0.01 : Fig. 3).”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Comparisons of methods of assessing ~3-cell function
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and with the estimate from the intravenous glucose tolerance test (R~ = 0.64, p < 0.05).”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Summary.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and in both groups together: 1% = 0.64, p< 0.05; Fig. 3).”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > HOMA compared with intravenous glucose tolerance test.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neither receptor numbers or any aspect of high or low affinity binding correlated with other measures of insulin resistance (HOMA, clamp, basal insulin or CIGMA: ~ all < 0.55; NS).”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > HOMA compared with the hyperglycaemic clamp. The
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
- It may state two separate claims as one. 2
- The quote only partly states this claim. 1
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The low precision of the estimates from the model (coefficients of variation: 31% for insulin resistance and 32% for/3-cell deficit) limits its use”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Summary.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean coefficient of variation over the two studies was 31%.”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Hyperglycaemic clamp : ~-cell function (%)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The degree of the hyperglycaemia does not correlate significantly with either the degrees of abnormal fl-cell function or insulin resistance.”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
- Rests on an assumption: The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
The authors state this as an assumption.
Normal-weight normal subjects aged <35 years have 100% beta-cell function and an insulin resistance of 1.
“Assuming that normal-weight normal subjects aged < 35 years have 100% r-cell function, and an insulin resistance of 1, the values for a patient can be assessed from the insulin and glucose concentrations by the formulae: r-cell”
The paper relies on this without support.
The plasma glucose:insulin response for normal subjects is equivalent to the C-peptide response and is insulin = 5 (glucose-3.5).
“The plasma glucose:insulin response for normal subjects, equivalent to the C-peptide response, is insulin = 5 (glucose-3.5).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surrogate markers of peripheral insulin activity, such as homeostasis model assessment and whole-body insulin sensitivity indexes, could be useful as well in the early identification of patients with IR, before overt DM sets in ().”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [240]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“After the unprocessed diet, fasting glucose and insulin levels tended to decrease compared to baseline and the homeostasis model assessment of insulin resistance (HOMA-IR) (Matthews et al., 1985) was significantly decreased compared to baseline.”
From Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake (2019) · cites this paper as Matthews et al., 1985
The cited source says what the claim attributes to it.
In the citing paper
“The Homeostasis Model Assessment of Insulin Resistance (HoMA-IR) was calculated according to Matthews et al. [25].”
From Chronotype: A Tool to Screen Eating Habits in Polycystic Ovary Syndrome? (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“AAV9-mTERT treated mice also showed a trend for an improved glucose uptake and a better homeostatic model assessment (HOMA (Heikkinen et al, 2007; Matthews et al, 1985)) compared to the AAV9-eGFP controls, although differences did not reach statistical significance (Supporting Information Fig S4D and E).”
From Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer (2012) · cites this paper as Matthews et al, 1985
In the citing paper
“ndirect estimates of insulin resistance, such as HOMA-IR 63 and QUICKI, 64 are derived from fasting S-insulin and glucose concentrations and have been widely used in both nondiabetic and type 2 diabetic subjects as surrogates of insulin sensitivity.65,66”
From Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. (2008) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > Subjects and procedures
“The same 12 normal subjects and 11 Type 2 diabetic patients came to the hospital fasting on a separate day for a continuous infusion”
§ Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man > HOMA compared with the hyperglycaemic clamp. The
“HOMA compared with CIGMA.The HOMA estimate of insulin resistance from the mean of 15 stressed fasting samples before the CIGMA correlated with that measured by CIGMA in 11 normal subjects (R~ = 0.69, p < 0.02), in 12 diabetic subjects (R~ 0.97, p < 0.0001)”
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Quantitative estimation of insulin sensitivity.
Bergman, R. N., Ider, Y. Z., Bowden, C. R., & Cobelli, C. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.6.e667 · Cited by 1,874 · cited 1×
“This use of modelling to provide a reference graph contrasts with other models where an individual patient's data have to be entered into a computer to determine the relationships between rapidly changing variables, such as occur after an intravenous glucose test [19].”
Method[WHO Expert Committee on diabetes mellitus].
Reitsma, W. D., & Terpstra, J. (1981) · PubMed · Cited by 556
Turner, R. C., Holman, R. R., Matthews, D., Hockaday, T. D. R., & Peto, J. (1979) · Metabolism · doi:10.1016/0026-0495(79)90146-x · Cited by 388
Self-citationCharacteristics of Human Erythrocyte Insulin Receptors
Gambhir, K. K., Archer, J. A., & BRADLEY, C. J. (1978) · Diabetes · doi:10.2337/diab.27.7.701 · Cited by 290
The Insulin Receptor: Its Role in Insulin Resistance of Obesity and Diabetes
Olefsky, J. M. (1976) · Diabetes · doi:10.2337/diab.25.12.1154 · Cited by 289
Hosker, J. P., Matthews, D. R., Rudenski, A. S., Burnett, M. A., Darling, P., Bown, E. G., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280882 · Cited by 287
Self-citationPulsatile Insulin Has Greater Hypoglycemic Effect Than Continuous Delivery
Matthews, D. R., Naylor, B. A., Jones, R., Ward, G. M., & Turner, R. C. (1983) · Diabetes · doi:10.2337/diab.32.7.617 · Cited by 256
Self-citationControl of pulsatile insulin secretion in man
Matthews, D. R., Lang, D. A., Burnett, M. A., & Turner, R. C. (1983) · Diabetologia · doi:10.1007/bf00282705 · Cited by 175
Self-citationTHE BASAL PLASMA GLUCOSE: A SIMPLE RELEVANT INDEX OF MATURITY‐ONSET DIABETES
HOLMAN, R. R., & TURNER, R. C. (1981) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1981.tb00196.x · Cited by 64
Self-citation
Research works printed but not linked: 2
- Metropolitan Life Assurance Co (1959) Net weight standard for men and women. Stat Bull Metrol Life Found 40: 1?4
- Matthews DR, Hosker JP (1984) An unbiased, flexible computer programme for glucose clamping, with graphics and running statistics. Diabetologia 27: 308?309 A
Cited by
Sorted by citations
Items 12,501–12,600 of 31,469
Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release
Garduño‐García, J. D. J., Gastaldelli, A., DeFronzo, R. A., Lertwattanarak, R., Holst, J. J., & Musi, N. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00260 · Cited by 29
Wanderley, M. D. S., Pereira, L. C. R., Santos, C. B., da Cunha, V. S., & Neves, M. V. J. (2018) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0038-1642634 · Cited by 31
Imai, Y., Fink, B. D., Promes, J. A., Kulkarni, C. A., Kerns, R. J., & Sivitz, W. I. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.393 · Cited by 27
Pitchika, A., Jolink, M., Winkler, C., Hummel, S., Hummel, N., Krumsiek, J., Kastenmüller, G., Raab, J., Kordonouri, O., Ziegler, A., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4688-x · Cited by 27
Type 2 Diabetes Treatment and Drug Development Study
Lu, D.-Y., Che, J.-Y., Yarla, N. S., Wu, H., Lu, T.-R., Xu, B., Wu, S., Ding, J., Lü, Y., & Zhu, H. (2018) · The Open Diabetes Journal · doi:10.2174/1876524601808010022 · Cited by 27
Bo, S., Rahimi, F., Goitre, I., Properzi, B., Ponzo, V., Regaldo, G., Boschetti, S., Fadda, M., Ciccone, G., Daga, G. A., et al. (2018) · Obesity · doi:10.1002/oby.22262 · Cited by 30
Gæde, J., Nielsen, T., Madsen, M., et al. (2018) · Nutrition Journal · doi:10.1186/s12937-018-0395-1 · Cited by 27
Çelik, N., Aydın, S., Uğur, K., Yardım, M., Acet, M., Yavuzkır, Ş., Sahin, Ć., & Çelik, Ö. (2018) · Cellular and Molecular Biology · doi:10.14715/cmb/2017.64.15.2 · Cited by 27
Hong, A. R., Kim, J. H., Lee, J. H., et al. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0980-6 · Cited by 27
Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease.
Polyzos, S., Kountouras, J., Mavrouli, M., Katsinelos, P., Doulberis, M., Gavana, E., & Duntas, L. (2019) · Experimental and clinical endocrinology & diabetes · doi:10.1055/a-0811-9136 · Cited by 26
Ostermann, A. L., Wunderlich, C. M., Schneiders, L., Vogt, M. C., Woeste, M., Belgardt, B., Niessen, C. M., Martiny, B., Schauss, A. C., Frommolt, P., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0037-8 · Cited by 28
Suhett, L., Hermsdorff, H. H., Rocha, N. P., Silva, M. A., Filgueiras, M. D. S., Milagres, L. C., Pelúzio, M. C. G., & de Novaes, J. F. (2019) · Cardiology Research and Practice · doi:10.1155/2019/3904568 · Cited by 25
Fernström, M., Fernberg, U., & Hurtig‐Wennlöf, A. (2019) · BMC Nutrition · doi:10.1186/s40795-019-0279-6 · Cited by 27
Low concordance between HbA1c and OGTT to diagnose prediabetes and diabetes in overweight or obesity
Chatzianagnostou, K., Vigna, L., Piazza, S. D., Tirelli, A. S., Napolitano, F., Tomaino, L., Bamonti, F., Traghella, I., & Vassalle, C. (2019) · Clinical Endocrinology · doi:10.1111/cen.14043 · Cited by 26
Calza, L., Colangeli, V., Borderi, M., et al. (2019) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2019.1629008 · Cited by 27
Moriyama, K. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0024 · Cited by 27
Zhu, X., Qiu, Z., Ouyang, W., Miao, J., Xiong, P., Mao, D., Feng, K., Li, M., Luo, M., Xiao, H., et al. (2019) · Food Research International · doi:10.1016/j.foodres.2019.108570 · Cited by 27
Min, T., Prior, S. L., Churm, R., Dunseath, G. J., Barry, J. D., & Stephens, J. W. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04116-8 · Cited by 27
Schinzari, F., Tesauro, M., Bertoli, A., Valentini, A., Veneziani, A., Campia, U., & Cardillo, C. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00204.2019 · Cited by 27
Association of low serum magnesium with diabetes and hypertension: Findings from Qatar Biobank study
Shi, Z., & Abou‐Samra, A. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107903 · Cited by 27
Tecer, D., Sunar, İ., Özdemirel, A. E., Tural, R., Küçükşahin, O., Dinçel, A. S., & Ataman, Ş. (2019) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-019-0096-2 · Cited by 27
Cheng, X., Yang, N. Y., Li, Y., et al. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0446-4 · Cited by 27
Ting, Y., Wong, S., Zaini, A. A., Mohamed, R. B., & Jalaludin, M. Y. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00491 · Cited by 27
Jiang, Y., Qi, J., Xue, X., Huang, R., Zheng, J., Liu, W., Yin, H., & Li, S. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1698026 · Cited by 27
Aresta, C., Passeri, E., & Corbetta, S. (2019) · International Journal of Endocrinology · doi:10.1155/2019/7617254 · Cited by 27
Yavuzkır, Ş., Uğur, K., Deniz, R., Üstebay, D. Ü., Mirzaoglu, M., Yardım, M., Şahin, İ., Baykuş, Y., Karagöz, Z. K., & Aydın, S. (2020) · Peptides · doi:10.1016/j.peptides.2020.170277 · Cited by 27
Abdel‐Hakeem, E. A., Abdel‐Hamid, H. A., & Hafez, S. M. N. A. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126480 · Cited by 27
Rutter, M. M., Wong, B. L. Y., Collins, J. J., Sawnani, H., Taylor, M. D., Horn, P. S., & Backeljauw, P. F. (2020) · Muscle & Nerve · doi:10.1002/mus.26846 · Cited by 27
Lahiji, M. R., Najafi, S., Janani, L., Yazdani, B., Razmpoosh, E., & Zarrati, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.05.043 · Cited by 27
Aquilani, R., Costa, A. C., Maestri, R., Ramusino, M. C., Pierobon, A., Dossena, M., Solerte, S. B., Condino, A. M., Torlaschi, V., Bini, P., et al. (2020) · Nutrients · doi:10.3390/nu12061845 · Cited by 27
Jimenez, M. P., Oken, E., Gold, D. R., Luttmann‐Gibson, H., Réquia, W. J., Rifas‐Shiman, S. L., Gingras, V., Hivert, M., Rimm, E. B., & James, P. (2020) · Environment International · doi:10.1016/j.envint.2020.105849 · Cited by 30
Hamamura, H., Adachi, H., Enomoto, M., Fukami, A., Nakamura, S., Nohara, Y., Morikawa, N., Sakaue, A., Toyomasu, K., Yamamoto, M., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.56390 · Cited by 27
Nonfunctioning Adrenal Incidentalomas are not Clinically Silent: A Longitudinal Cohort Study
Kim, J. H., Kim, M. J., Lee, J. H., Yoon, J. W., & Shin, C. S. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0182 · Cited by 27
Aranda-Valera, I. C., de la Rosa, I. A., Roldán‐Molina, R., Ábalos-Aguilera, M. D. C., Torres-Granados, C., Patiño-Trives, A. M., Luque-Tévar, M., Ibáñez‐Costa, A., Guzmán‐Ruiz, R., Malagón, M. M., et al. (2020) · Pediatric Rheumatology · doi:10.1186/s12969-020-00448-3 · Cited by 27
Akter, S., Eguchi, M., Kochi, T., et al. (2020) · Nutrients · doi:10.3390/nu12082344 · Cited by 27
Nowrouzi‐Sohrabi, P., Hassanipour, S., Sisakht, M., Daryabeygi‐Khotbehsara, R., Savardashtaki, A., & Fathalipour, M. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.07.052 · Cited by 27
Kruse, M., Kemper, M., Gancheva, S., Osterhoff, M. A., Dannenberger, D., Markgraf, D. F., Machann, J., Hierholzer, J., Roden, M., & Pfeiffer, A. F. H. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000419 · Cited by 27
Zhao, F. Q., Dong, T., Yuan, K.-Y., Wang, N., Xia, F., Liu, D., Wang, Z., Ma, R., Lu, Y., & Huang, Z. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.581888 · Cited by 27
Gawędzka, A., Grandys, M., Duda, K., Zapart-Bukowska, J., Zoladz, J. A., & Majerczak, J. (2020) · PeerJ · doi:10.7717/peerj.10491 · Cited by 28
Ye, Z., Zhang, C., & Zhao, Y. (2021) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2021.01.020 · Cited by 27
An, S., Niu, D., Wang, T., et al. (2021) · Foods · doi:10.3390/foods10030670 · Cited by 27
Trub, C. J., Balikcioglu, M., Freemark, M., Bain, J. R., Muehlbauer, M. J., Ilkayeva, O., White, P. J., Armstrong, S., Østbye, T., Grambow, S. C., et al. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.250 · Cited by 29
Álvarez‐Amor, L., Luque‐Sierra, A., Cárdenas, A., López-Bermudo, L., López‐Beas, J., Andújar, E., Pérez-Alegre, M., Gallego‐Durán, R., Varela, L. M., Martín‐Montalvo, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87761-3 · Cited by 28
Dieli-Conwright, C. M., Courneya, K. S., Demark‐Wahnefried, W., Sami, N., Norris, M. K., Fox, F., Buchanan, T. A., SPICER, D. V., Bernstein, L., & Tripathy, D. (2021) · SLEEP · doi:10.1093/sleep/zsab111 · Cited by 27
Dare, A., Channa, M. L., & Nadar, A. (2021) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0247 · Cited by 29
Impact of Obstructive Sleep Apnea on Gestational Diabetes Mellitus
Alonso‐Fernández, A., Moncadas, M. C., Larrínaga, A. Á. R. D., Barón, A. S., Marcet, M. C., Rodríguez, P., Gómez, A. V. G., Giménez, P., Martínez, C. P., Marin, J. P. C., et al. (2021) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.05.005 · Cited by 27
Overweight/obesity in adolescents with phenylketonuria: protective and predisposing factors
Silveira, A. M., Lima, P. L., Alves, M. R. A., Soares, R. D. L., Kanufre, V. D. C., Rodrigues, V. D. M., Starling, A. L. P., Norton, R. D. C., & de Aguiar, M. J. B. (2021) · Jornal de Pediatria · doi:10.1016/j.jped.2021.04.009 · Cited by 27
Tovar, R., Gavito, A., Vargas, A., Soverchia, L., Hernández‐Folgado, L., Jagerovic, N., Baixerás, E., Ciccocioppo, R., de Fonseca, F. R., & Decara, J. M. (2021) · Nutrients · doi:10.3390/nu13082589 · Cited by 27
Di(2-ethylhexyl)phthalate exposure exacerbates metabolic disorders in diet-induced obese mice
Hsu, J.-W., Nien, C.-Y., Chen, H., Tsai, F., Yeh, S., Kao, Y.-H., & Tsou, T. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112439 · Cited by 29
Wongmekiat, O., Lailerd, N., Kobroob, A., & Peerapanyasut, W. (2021) · Biomolecules · doi:10.3390/biom11081224 · Cited by 28
Tang, Z., Ming, Y., Wu, M., Jing, J., Xu, S., Li, H., & Zhu, Y. (2021) · Nutrients · doi:10.3390/nu13093222 · Cited by 28
Ishimwe, M. C. S., Wentzel, A., SHOUP, E. M., OSEI-TUTU, N. H., Hormenu, T., Patterson, A. C., Bagheri, H., DuBose, C. W., Mabundo, L. S., Ha, J., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002447 · Cited by 33
Lee, C., Kim, H. J., Chang, T. I., Kang, E. W., Joo, Y. S., Kim, H. W., Park, J. T., Yoo, T., Kang, S., & Han, S. H. (2021) · Aging · doi:10.18632/aging.203539 · Cited by 28
Meloni, A., Pistoia, L., Gamberini, M. R., Ricchi, P., Cecinati, V., Sorrentino, F., Cuccia, L., Allò, M., Righi, R., Fina, P., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235561 · Cited by 28
Qian, H., Xu, J., Gu, J. L., et al. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104890 · Cited by 27
Czarniak, P., Ahmadizar, F., Hughes, J., Parsons, R. W., Kavousi, M., Ikram, M. A., & Stricker, B. H. C. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15182 · Cited by 27
Muratsu, J., Kamide, K., Fujimoto, T., Takeya, Y., Sugimoto, K., Taniyama, Y., Morishima, A., Sakaguchi, K., Matsuzawa, Y., & Rakugi, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.805244 · Cited by 27
Metabolic variables of obese dogs with insulin resistance supplemented with yeast beta-glucan
Ferreira, C. S., Vendramini, T. H. A., Amaral, A. R., Rentas, M. F., Ernandes, M. C., da Silva, F. L., Oba, P. M., Filho, F. D. O. R., & Brunetto, M. A. (2022) · BMC Veterinary Research · doi:10.1186/s12917-021-03106-2 · Cited by 30
Belladelli, F., Boeri, L., Pozzi, E., Fallara, G., Corsini, C., Candela, L., Cazzaniga, W., Cignoli, D., Pagliardini, L., d’Arma, A., et al. (2022) · Metabolites · doi:10.3390/metabo12020143 · Cited by 31
Williams, R. A., Cooper, S. B., Dring, K. J., Hatch, L. M., Morris, J. G., Sun, F., & Nevill, M. E. (2022) · BMC Pediatrics · doi:10.1186/s12887-022-03118-3 · Cited by 27
Nelson, A. B., Chow, L. S., Stagg, D. B., Gillingham, J. R., Evans, M. D., Pan, M., Hughey, C. C., Myers, C. L., Han, X., Crawford, P. A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158037 · Cited by 29
Xue, J., Liang, S., Ma, J., & Xiao, Y. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00967-y · Cited by 29
Gu, P., Jiang, W., Chen, M., Lü, B., Shao, J., Du, H., & Jiang, S. (2012) · PubMed · doi:10.3275/8238 · Cited by 27
Yoo, T. K., Oh, B. K., Lee, M. Y., & Sung, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-10032-2 · Cited by 29
Qushawy, M. K. E., Mortagi, Y. I., Alshaman, R., Mokhtar, H. I., Hisham, F. A., Alattar, A., Liang, D., Enan, E. T., Eltrawy, A. H., Alamrani, Z. H., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15070864 · Cited by 27
Wang, T., Zheng, L. P., Wang, S., Zhao, M., & Liu, X. (2022) · Food Science and Human Wellness · doi:10.1016/j.fshw.2022.06.020 · Cited by 29
Zhang, Y., Gao, F., Gong, H., Fu, Y., Liu, B., Qin, X., & Zheng, Q. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166638 · Cited by 32
Zuccotti, G., Calcaterra, V., Mannarino, S., D'Auria, E., Bova, S., Fiori, L., Verduci, E., Milanese, A., Marano, G., Garbin, M., et al. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1080654 · Cited by 24
Berbrier, D. E., Leone, C. A., Adler, T. E., Bender, J. R., Taylor, H. S., Stachenfeld, N. S., & Usselman, C. W. (2023) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00583.2022 · Cited by 27
Circulating miRNAs in Women with Polycystic Ovary Syndrome: A Longitudinal Cohort Study
Udesen, P. B., Sørensen, A. E., Svendsen, R. P., Frisk, N. L. S., Hess, A. L., Aziz, M., Wissing, M. L., Englund, A. L. M., & Dalgaard, L. T. (2023) · Cells · doi:10.3390/cells12070983 · Cited by 26
Shamardl, H. A., Ibrahim, N. A., Merzeban, D. H., Elamir, A. M., Golam, R. M., & Elsayed, A. M. (2023) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-023-00458-y · Cited by 27
Minato-Inokawa, S., Tsuboi-Kaji, A., Honda, M., Takeuchi, M., Kitaoka, K., Kurata, M., Wu, B., Kazumi, T., & Fukuo, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-35001-1 · Cited by 28
Safari, Z., Bagherniya, M., Khoram, Z., Varzaneh, A. E., Heidari, Z., Sahebkar, A., & Askari, G. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1163950 · Cited by 30
Ke, Z., Huang, R., Xu, X., Liu, W., Wang, S.-S., Zhang, X., Guo, Y., Zhuang, X., & Liao, L. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028985 · Cited by 27
Alidu, H. W., Dapare, P. P. M., Quaye, L., Amidu, N., Bani, S. B., & Banyeh, M. (2023) · BioMed Research International · doi:10.1155/2023/8873226 · Cited by 34
Gu, P., Pu, B., Qiao, X., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32931-8 · Cited by 27
Diabetes detection in women with gestational diabetes and polycystic ovarian syndrome
Hanna, F., Wu, P., Heald, A. H., & Fryer, A. A. (2023) · BMJ · doi:10.1136/bmj-2022-071675 · Cited by 32
High-Dose Glucocorticoids for the Treatment of Sudden Hearing Loss
Plontke, S. K., Girndt, M., Meisner, C., Fischer, I. U., Böselt, I., Löhler, J., Ludwig‐Kraus, B., Richter, M., Steighardt, J., Reuter, B., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300172 · Cited by 35
Dobutović, B., Sudar-Milovanovic, E. M., Tepavčević, S., Djordjevic, J., Djordjevic, A. D., Radojcic, M. B., & Isenović, E. R. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.44872 · Cited by 27
Retinol binding protein‐4 predicts incident diabetes in A sian I ndian men with prediabetes
Jagannathan, R., Snehalatha, C., Selvam, S., Nanditha, A., Shetty, A. S., Godsland, I. F., Johnston, D. G., & Ramachandran, A. (2015) · BioFactors · doi:10.1002/biof.1209 · Cited by 28
Mu, P., Chen, Y., Lu, H., Wen, X., Zhang, Y., Xie, R., Shu, J., Wang, M., & Zeng, L. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1292 · Cited by 27
Apelin and G212A apelin receptor gene polymorphism in obese and diabese youth
Kotanidou, E. P., Kalinderi, K., Kyrgios, I., et al. (2014) · Pediatric Obesity · doi:10.1111/ijpo.251 · Cited by 27
Variability of formulas to assess insulin sensitivity and their association with the Matsuda index.
Henríquez, S., Jara, N., Bunout, D. C., Hirsch, S., de la Maza, M. P., Leiva, L., & Barrera, G. (2013) · PubMed · doi:10.3305/nh.2013.28.5.6512 · Cited by 27
Toll-like receptor 4 gene (Asp299Gly) polymorphism associates with carotid artery elasticity
Hernesniemi, J. A., Raitakari, O. T., Kähönen, M. A. P., Juonala, M., Hutri‐Kähönen, N., Marniemi, J., Viikari, J. S. A., & Lehtimäki, T. J. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.024 · Cited by 27
Lee, S. H., Lee, J. A., Park, H. S., Song, Y., Jang, Y. J., Kim, J. H., Lee, Y. J., & Heo, Y. (2013) · Obesity · doi:10.1002/oby.20183 · Cited by 30
Yang, Y., Feng, Y., Ma, X., Chen, K.-T., Wu, N., Wang, D., Li, P., Wang, M., Li, Q., & Zhang, J. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2615 · Cited by 28
Assar, M. E., Sánchez-Puelles, J.-M., Royo, I., López‐Hernández, E., Sánchez‐Ferrer, A., Aceña, J. L., Rodríguez‐Mañas, L., & Angulo, J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12993 · Cited by 27
YKL‐40 in type 2 diabetic patients with different levels of albuminuria
Brix, J. M., Höllerl, F., Koppensteiner, R., Schernthaner, G., & Schernthaner, G.-H. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02446.x · Cited by 27
Ooi, D. S. Q., Chan, R. M. E., Poh, L. K. S., Loke, K. Y., Heng, C., Chan, Y. H., Gan, S. U., Lee, K., & Lee, Y. S. (2013) · Pediatric Obesity · doi:10.1111/j.2047-6310.2013.00149.x · Cited by 27
Che, J., Li, G., Wang, W., Li, Q., Liu, H., Chen, K., & Liu, T. (2011) · PubMed · Cited by 27
O’Sullivan, T. A., Lyons‐Wall, P., Bremner, A., Ambrosini, G. L., Huang, R., Beilin, L. J., Mori, T. A., Blair, E. M., & Oddy, W. H. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03021.x · Cited by 27
Raab, J., Haupt, F., Kordonouri, O., Scholz, M., Wosch, A., Ried, C., Aschemeier, B., Danne, T., Ziegler, A., & Winkler, C. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2438 · Cited by 27
Zeelie, A., Moss, S. J., & Kruger, H. S. (2010) · Nutrition · doi:10.1016/j.nut.2010.03.001 · Cited by 27
Screening Markers of Impaired Glucose Tolerance in the Obese Pediatric Population
Tsay, J., Pomeranz, C. B., Hassoun, A. A., Zandieh, S., Rutledge, J., Vogiatzi, M. G., Oberfield, S. E., & Motaghedi, R. (2010) · Hormone Research in Paediatrics · doi:10.1159/000277625 · Cited by 27
Hzf regulates adipogenesis through translational control of C/EBPα
Kawagishi, H., Wakoh, T., Uno, H., Maruyama, M., Moriya, A., Morikawa, S., Okano, H., Sherr, C. J., Takagi, M., & Sugimoto, M. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.76 · Cited by 28
Insulin resistance relates to microvascular reactivity 23 years after preeclampsia
Spaan, J. J., Houben, A. J. H. M., Musella, A., Ekhart, T. H. A., Spaanderman, M. E. A., & Peeters, L. L. H. (2010) · Microvascular Research · doi:10.1016/j.mvr.2010.07.003 · Cited by 27
Kim, C., Kim, H., Bae, S., Park, J., & Lee, K.-U. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.09.025 · Cited by 27
Coşkun, B. D. Ö., Yücesoy, M., Gürsoy, Ş., Başkol, M., Yurçi, A., Yağbasan, A., Doğan, S., & Başkol, G. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000264 · Cited by 28
Martínez‐Hervás, S., Argente, C. R., Jodar, J. G., Priego, A., Real, J. T., Carratalá, A., Carmena, R., & Ascaso, J. F. (2010) · Metabolism · doi:10.1016/j.metabol.2010.07.024 · Cited by 26
Marino, L. D., Maffettone, A., Cipriano, P., Sacco, M., Palma, R. D., Amato, B., Quarto, G., Riccardi, G., & Rivellese, A. A. (2000) · Metabolism · doi:10.1053/meta.2000.8616 · Cited by 27
Metadata
- Authors
- Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C.
- Affiliations
- University of Oxford (GB)
- ORCID
- Matthews, D. R.
- Venue
- Diabetologia
- Published
- 1985-07
- Volume
- 28
- Issue
- 7
- Pages
- 412-419
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2160234571
- Cited by
- 31,502
- References
- 21
- Citations by year
- 2026: 933 · 2025: 1060 · 2024: 1240 · 2023: 1291 · 2022: 1489 · 2021: 1528 · 2020: 1424 · 2019: 1427 · 2018: 1456 · 2017: 1440 · 2016: 1481 · 2015: 1682 · 2014: 1693 · 2013: 1621 · 2012: 1518
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- HOMA, insulin resistance, beta-cell function, fasting blood glucose, fasting insulin, hyperglycaemic clamp, euglycaemic clamp, intravenous glucose tolerance test, insulin receptor binding, type 2 diabetes
- MeSH terms
- Adult, Blood Glucose, Computers, Diabetes Mellitus, Type 2, Erythrocytes, Fasting, Homeostasis, Humans, Insulin, Insulin Resistance, Islets of Langerhans, Middle Aged, Monocytes, Receptor, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-14, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-14 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
